TXMD RSI Chart
Last 7 days
-5.4%
Last 30 days
-20.4%
Last 90 days
-23.6%
Trailing 12 Months
-55.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 52.8M | 35.6M | 18.5M | 1.3M |
2022 | 67.8M | 45.1M | 57.5M | 70.0M |
2021 | 72.5M | 84.8M | 90.9M | 87.0M |
2020 | 58.0M | 62.6M | 58.2M | 64.9M |
2019 | 16.3M | 18.6M | 38.8M | 49.6M |
2018 | 16.6M | 16.1M | 15.1M | 16.1M |
2017 | 18.4M | 18.3M | 17.1M | 16.8M |
2016 | 20.6M | 20.2M | 20.5M | 19.4M |
2015 | 16.7M | 17.8M | 18.8M | 20.1M |
2014 | 10.3M | 11.7M | 13.6M | 15.0M |
2013 | 0 | 5.5M | 7.1M | 8.8M |
2012 | 2.3M | 2.6M | 3.1M | 3.8M |
2011 | 1.5M | 1.7M | 1.9M | 2.1M |
2010 | 0 | 0 | 0 | 1.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 07, 2023 | walker marlan d | sold | -10,187 | 2.239 | -4,550 | chief executive officer |
Dec 06, 2023 | walker marlan d | sold | -33,496 | 2.3101 | -14,500 | chief executive officer |
Dec 05, 2023 | walker marlan d | acquired | - | - | 70,000 | chief executive officer |
Nov 15, 2023 | rubric capital management lp | acquired | 2,000,000 | 2.28 | 877,192 | - |
Aug 17, 2023 | ziegler joseph | acquired | - | - | 7,500 | principal financial officer |
Jun 28, 2023 | rubric capital management lp | acquired | 1,150,000 | 3.6797 | 312,525 | - |
Apr 26, 2023 | walker marlan d | sold | -2,517 | 3.6381 | -692 | chief executive officer |
Apr 26, 2023 | walker marlan d | acquired | - | - | 2,744 | chief executive officer |
Apr 12, 2023 | walker marlan d | sold | -4,275 | 3.6543 | -1,170 | chief executive officer |
Apr 12, 2023 | walker marlan d | acquired | - | - | 7,508 | chief executive officer |
Which funds bought or sold TXMD recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Jun 11, 2024 | EverSource Wealth Advisors, LLC | new | - | 2.00 | 2.00 | -% |
May 15, 2024 | Clearline Capital LP | added | 14.83 | 176,954 | 1,225,930 | 0.06% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 1,204 | 68,929 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -0.06 | 5,099 | 301,575 | -% |
May 15, 2024 | AMERIPRISE FINANCIAL INC | reduced | -0.04 | 877 | 51,456 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -2.2 | -4.00 | 916 | -% |
May 15, 2024 | BARCLAYS PLC | sold off | -100 | - | - | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | unchanged | - | 10,886 | 623,246 | 0.14% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 14,781 | 3,724 | 3,749 | -% |
May 15, 2024 | J. Goldman & Co LP | unchanged | - | 542 | 31,057 | -% |
Unveiling TherapeuticsMD Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Nov 17, 2023 | rubric capital management lp | 25.73% | 2,946,908 | SC 13D/A | |
Jun 30, 2023 | rubric capital management lp | 19.57% | 2,069,716 | SC 13D/A | |
Aug 30, 2022 | rubric capital management lp | 18.27% | 1,721,953 | SC 13D/A | |
Jul 08, 2022 | blackrock inc. | 1.4% | 122,138 | SC 13G/A | |
Jun 03, 2022 | beryl capital management llc | 1.5% | 126,229 | SC 13G | |
Mar 23, 2022 | smith robert j | 5.38% | 23,103,292 | SC 13D/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 0.1% | 649,807 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 5.9% | 24,894,812 | SC 13G/A | |
Jul 07, 2021 | flynn james e | 4.90% | 20,662,810 | SC 13G | |
Feb 16, 2021 | price t rowe associates inc /md/ | 6.2% | 18,869,212 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Jun 14, 2024 | AW | AW | |
May 10, 2024 | 8-K | Current Report | |
May 10, 2024 | 10-Q | Quarterly Report | |
Apr 29, 2024 | 10-K/A | Annual Report | |
Mar 29, 2024 | 8-K | Current Report | |
Mar 29, 2024 | 10-K | Annual Report |
Peers (Alternatives to TherapeuticsMD Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 351.0B | 85.6B | 1.02% | -10.50% | 9.12 | 4.1 | 5.68% | 202.39% |
MRK | 328.9B | 61.4B | 2.97% | 15.47% | 142.61 | 5.36 | 6.11% | -82.30% |
AMGN | 168.3B | 29.5B | 4.50% | 41.74% | 44.72 | 5.7 | 12.76% | -52.47% |
PFE | 157.6B | 35.0B | -1.70% | -23.34% | 135.67 | 4.5 | -26.40% | -92.03% |
GILD | 85.8B | 27.4B | 7.65% | -9.65% | 176.99 | 3.12 | 1.51% | -91.32% |
TEVA | 18.3B | 16.0B | -2.98% | 116.80% | -36.93 | 1.14 | 7.23% | 71.10% |
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 2.23% | -25.66% | 9.46 | 2.38 | 54.01% | 364.56% |
PRGO | 3.5B | 4.6B | -6.95% | -23.47% | -450.21 | 0.76 | -0.06% | 94.55% |
BHC | 2.5B | 9.0B | 11.13% | -9.58% | -5.55 | 0.28 | 10.01% | -27.45% |
AMPH | 2.0B | 676.2M | -3.88% | -27.45% | 12.76 | 2.92 | 30.38% | 66.04% |
SMALL-CAP | ||||||||
TLRY | 1.3B | 743.2M | -4.95% | 9.49% | -3.8 | 1.8 | 24.65% | 80.36% |
TXMD | 20.2M | 1.3M | -20.45% | -55.70% | -2.72 | 15.5 | -98.14% | -104.71% |
ACRX | 15.5M | 89.6M | -11.65% | -13.33% | -1.09 | 0.19 | 287.27% | -129.41% |
AGRX | 9.8M | 21.5M | 276.32% | -42.34% | -1.26 | 0.46 | 66.16% | 61.84% |
ACOR | 322.9K | 115.7M | -61.54% | -97.23% | 0 | 0 | -2.22% | -352.48% |
TherapeuticsMD Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 6.9% | 502,000 | 469,500 | 437,000 | 414,750 | 392,500 | 370,250 | 348,000 | 695,000 | 18,678,000 | 25,406,000 | 23,001,000 | 19,866,000 | 22,578,000 | 19,342,000 | 10,701,000 | 12,251,000 | 15,902,000 | 23,719,000 | 6,079,000 | 3,947,000 | 5,089,000 |
Gross Profit | 1047.2% | 502,000 | -53,000 | 437,000 | 416,000 | 61,329,500 | - | - | 14,473,000 | 13,941,000 | 20,124,000 | 18,869,000 | 15,179,000 | 16,997,000 | 16,063,000 | 6,301,000 | 9,536,000 | 13,023,000 | 22,275,000 | 4,830,000 | 3,184,000 | 4,139,000 |
Operating Expenses | 22.8% | 2,113,000 | 1,720,000 | 2,909,000 | 3,083,000 | 20,124,000 | 14,519,000 | 14,857,000 | 17,875,000 | -77,802,000 | 60,045,000 | 54,048,000 | 44,457,000 | 51,604,000 | 41,037,000 | 51,339,000 | 60,458,000 | 57,414,537 | 49,346,683 | 46,466,878 | 41,288,902 | 42,259,406 |
S&GA Expenses | -7.2% | 1,476,000 | 1,590,000 | 2,781,000 | 3,056,000 | 10,343,000 | 14,246,000 | 14,575,000 | 17,546,000 | -5,445,000 | 30,005,000 | 32,164,000 | 24,024,000 | 16,799,500 | 22,373,000 | 29,887,000 | 57,189,000 | -7,147,519 | 45,126,986 | 41,387,451 | 34,864,082 | 35,410,875 |
R&D Expenses | - | - | - | - | - | - | 1,112,000 | 1,580,000 | 1,400,000 | 1,420,000 | 1,605,000 | 2,011,000 | 2,050,000 | 2,394,000 | 2,027,000 | 2,742,000 | 3,269,000 | 4,432,012 | 4,077,738 | 4,964,368 | 6,317,882 | 6,753,190 |
EBITDA Margin | -279.6% | -5.24 | 2.92 | 1.14 | 0.54 | 0.26 | 0.11 | -0.40 | -0.55 | -0.62 | -1.47 | -1.41 | -1.80 | -2.34 | - | - | - | - | - | - | - | - |
Interest Expenses | -100.0% | - | 20,000 | 45,000 | 50,000 | 10,863,000 | - | - | 5,364,000 | -273,000 | 7,518,000 | 7,596,000 | 10,227,000 | 7,612,000 | 7,680,000 | 7,027,000 | 6,262,000 | 5,664,368 | 5,599,005 | 4,028,609 | 2,090,018 | 2,093,375 |
Income Taxes | - | - | - | - | - | - | -260,000 | 550,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -10.5% | -1,584,000 | -1,434,000 | -2,414,000 | -2,310,000 | 48,453,000 | -14,631,000 | -14,873,000 | -17,875,000 | 50,150,000 | -47,420,000 | -42,652,000 | -39,383,000 | -42,087,000 | -32,612,000 | -51,976,000 | -56,849,000 | -49,435,515 | -31,966,593 | -55,236,517 | -39,506,375 | -39,390,981 |
EBT Margin | -359.6% | -5.95 | 2.29 | 0.82 | 0.32 | 0.02 | 0.05 | -0.67 | -0.85 | -0.91 | -1.89 | -1.85 | -2.29 | -2.83 | - | - | - | - | - | - | - | - |
Net Income | 73.9% | -883,000 | -3,378,000 | -2,414,000 | -3,603,000 | 77,702,000 | -28,965,000 | 112,281,000 | -49,021,000 | -42,960,000 | -47,420,000 | -42,652,000 | -39,383,000 | -42,087,000 | -32,612,000 | -51,976,000 | -56,849,000 | -49,435,000 | -31,967,000 | -55,237,000 | -39,506,000 | -39,391,000 |
Net Income Margin | -313.4% | -7.89 | 3.70 | 1.20 | 2.98 | 1.60 | -0.15 | -0.60 | -2.69 | -1.98 | -1.89 | -1.85 | -2.29 | -2.83 | - | - | - | - | - | - | - | - |
Free Cashflow | 17.7% | -4,960,000 | -6,028,000 | -3,392,000 | -8,701,000 | 30,236,000 | 17,716,000 | -20,700,000 | -17,914,000 | 48,002,000 | -38,153,000 | -26,573,000 | -38,443,000 | -30,525,000 | - | - | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.8% | 42.00 | 43.00 | 50.00 | 54.00 | 60.00 | 90.00 | 134 | 146 | 133 | 169 | 210 | 211 | 239 | 182 | 177 | 206 | 269 | 266 | 250 | 247 | 182 |
Current Assets | -2.3% | 12.00 | 12.00 | 17.00 | 20.00 | 25.00 | 55.00 | 87.00 | 99.00 | 84.00 | 119 | 160 | 160 | 187 | 128 | 122 | 149 | 212 | 208 | 192 | 216 | 153 |
Cash Equivalents | 0.3% | 4.00 | 4.00 | 49.00 | 49.00 | 49.00 | 49.00 | 65.00 | 65.00 | 65.00 | 65.00 | 105 | 111 | 138 | 80.00 | 80.00 | 114 | 170 | 161 | 155 | 183 | 123 |
Inventory | - | - | - | - | - | - | - | 7.00 | 6.00 | 9.00 | 8.00 | 7.00 | 8.00 | 7.00 | 8.00 | 10.00 | 10.00 | 15.00 | 12.00 | 11.00 | 7.00 | 5.00 |
Net PPE | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 1.00 | 1.00 |
Liabilities | -4.3% | 13.00 | 14.00 | 22.00 | 22.00 | 28.00 | 55.00 | 182 | 172 | 274 | 263 | 267 | 260 | 249 | 306 | 293 | 300 | 314 | 257 | 271 | 238 | 121 |
Current Liabilities | -5.6% | 6.00 | 7.00 | 15.00 | 14.00 | 19.00 | 47.00 | 174 | 164 | 265 | 253 | 86.00 | 76.00 | 61.00 | 59.00 | 47.00 | 46.00 | 62.00 | 53.00 | 67.00 | 42.00 | 45.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 172 | 175 | 179 | 238 | 237 | 244 | 243 | 195 | 194 | 194 | 74.00 |
LT Debt, Current | - | - | - | - | - | - | - | 94.00 | 91.00 | 203 | 188 | 15.00 | 10.00 | 5.00 | - | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | 172 | 175 | 179 | 238 | 237 | 244 | 243 | 195 | 194 | 194 | 74.00 |
Shareholder's Equity | -2.1% | 29.00 | 29.00 | 28.00 | 31.00 | 32.00 | 35.00 | - | - | - | - | - | - | - | - | - | - | - | 9.00 | - | 8.00 | 61.00 |
Retained Earnings | -0.1% | -950 | -949 | -948 | -945 | -942 | -939 | -1,017 | -988 | -1,100 | -1,051 | -1,008 | -960 | -918 | -878 | -836 | -804 | -752 | -695 | -645 | -614 | -558 |
Additional Paid-In Capital | 0.0% | 979 | 979 | 977 | 977 | 975 | 974 | 969 | 962 | 960 | 958 | 951 | 912 | 908 | 755 | 721 | 710 | 707 | 704 | 625 | 622 | 619 |
Shares Outstanding | 0% | 12.00 | 12.00 | 11.00 | 11.00 | 10.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 7.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 34.00 | - | - | - | 87.00 | - | - | - | 445 | - | - | - | 308 | - | - | - | 539 | - |
Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 95.4% | -229 | -4,960 | -6,028 | -3,392 | -8,701 | 30,236 | 17,716 | -20,721 | -17,872 | 48,002 | -38,223 | -26,532 | -38,380 | -30,357 | -34,049 | -55,954 | -39,111 | -50,817 | -26,222 | -50,514 | -38,163 |
Share Based Compensation | -4.3% | 111 | 116 | 234 | 438 | 483 | 2,985 | 4,292 | 2,234 | 2,061 | 5,346 | 7,312 | 2,510 | 2,957 | 5,245 | - | - | 2,366 | 4,333 | 2,195 | 56.00 | 2,587 |
Cashflow From Investing | - | - | - | - | - | - | -74.00 | 7.00 | -76.00 | -212 | -1,514 | -182 | -89.00 | -438 | -494 | -262 | -399 | -443 | -20,713 | -1,302 | -1,210 | -665 |
Cashflow From Financing | -100.0% | - | 2,002 | -1.00 | - | - | -111,945 | 1,739 | -120,000 | -5,000 | 1,353 | 31,822 | 428 | 95,949 | 31,703 | 106 | 94.00 | 48,822 | 77,031 | 9.00 | 111,687 | 100 |
Condensed Consolidated Statements of Comprehensive (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Selling, general and administrative | $ 1,322 | $ 3,056 |
Depreciation & amortization | 133 | 27 |
Total operating expenses | 1,455 | 3,083 |
Loss from operations | (1,142) | (2,667) |
Other income (expense) : | ||
Interest expense and other financing costs | (50) | |
Miscellaneous income (expense) | 333 | 407 |
Total other income, net | 333 | 357 |
Loss from continuing operations before income taxes | (809) | (2,310) |
Provision for income taxes | ||
Loss from continuing operations, net of income taxes | (809) | (2,310) |
Income (loss) from discontinued operations, net of income taxes | 75 | (1,293) |
Net loss | $ (734) | $ (3,603) |
Income (loss) per common share, basic and diluted: | ||
Continuing operations (in Dollars per share) | $ (0.07) | $ (0.24) |
Discontinued operations, net (in Dollars per share) | 0.01 | (0.13) |
Net loss per common share, basic (in Dollars per share) | $ (0.06) | $ (0.37) |
Weighted average common shares, basic (in Shares) | 11,532,000 | 9,754,000 |
Weighted average common shares, diluted (in Shares) | 11,532,000 | 9,754,000 |
License and service revenue | ||
Revenue, net: | ||
License and service revenue | $ 313 | $ 416 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,338 | $ 4,327 |
Royalty receivable, current portion | 3,222 | 3,090 |
Prepaid and other current assets | 3,869 | 4,035 |
Current assets of discontinued operations | 94 | 344 |
Total current assets | 11,523 | 11,796 |
License rights and other intangible assets, net | 5,965 | 6,098 |
Right of use assets | 6,687 | 6,873 |
Royalty receivable, long term | 17,855 | 18,484 |
Other non-current assets | 58 | 58 |
Total assets | 42,088 | 43,309 |
Current liabilities: | ||
Accounts payable | 139 | 27 |
Accrued expenses and other current liabilities | 2,720 | 3,133 |
Current liabilities of discontinued operations | 3,609 | 3,694 |
Total current liabilities | 6,468 | 6,854 |
Operating lease liabilities | 6,319 | 6,532 |
Other non-current liabilities | 637 | 636 |
Total liabilities | 13,424 | 14,022 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity: | ||
Common stock, par value $0.001; 32,000 shares authorized, 11,532 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 11 | 11 |
Additional paid-in capital | 979,028 | 978,917 |
Accumulated deficit | (950,375) | (949,641) |
Total stockholders’ equity | 28,664 | 29,287 |
Total liabilities and stockholders’ equity | $ 42,088 | $ 43,309 |
 WEBSITE | therapeuticsmd.com |
---|---|
 INDUSTRY | Pharmaceuticals |
 EMPLOYEES | 1 |